OVERVIEW

Innovative Therapies in Post-Transplant GVHD: Personal Insights From the Patient CaseBook is organized by PeerView Institute for Medical Education (PVI), Medical College of Wisconsin (MCW) and will be held from Mar 28, 2019 - Mar 27, 2020.

Target Audience:
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of patients with post-transplant GVHD.

Accreditation:
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Activity Description and Educational Objectives:
This activity utilizes a “CaseBook” format, offering learners a collection of patient case scenarios from the experts’ personal repertoire paired with analyses of how the treatment landscape in acute and chronic graft-versus-host disease (GVHD) is evolving. Hematology-oncology and bone marrow transplant professionals take a deep dive into the underlying immunology of GVHD and the latest evidence with innovative therapeutics while also obtaining expert perspectives on the practical application of these advancements as prophylaxis or for treatment of acute and chronic, steroid–nonresponsive, and previously untreated GVHD.

Upon completion of this activity, participants should be better able to:
• Describe the underlying immunology of post-transplant GVHD, and the rationale for and mechanisms of novel therapies in the management of GVHD
• Discuss the latest evidence on novel therapies, including JAK 1/2 inhibitors, BTK inhibitors, and T-cell costimulation modulators, for prophylaxis or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HSCT setting
• Apply the most optimal evidence-based strategies, including enrollment in clinical trials, for post-transplant GVHD care based on individual patient and disease characteristics

Additional details will be posted as soon as they are available.